ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,580
+420 (2.77%)
Dec 10, 2025, 3:30 PM KST
27.18%
Market Cap165.31B
Revenue (ttm)5.91B
Net Income (ttm)-17.78B
Shares Out10.90M
EPS (ttm)-1,643.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume172,748
Average Volume212,611
Open15,160
Previous Close15,160
Day's Range14,710 - 15,900
52-Week Range10,000 - 22,800
Betan/a
RSI65.41
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.

Financial Statements

News

There is no news available yet.